Usual Interstitial Pneumonia Pattern and Mycobacteria Lung Diseases: A Case Series
Abstract
:1. Introduction
Causes of UIP Pattern | References |
---|---|
Idiopathic pulmonary fibrosis | [1] |
Hypersensitivity pneumonitis | [9] |
Asbestos exposure | [9] |
Sarcoidosis | [10] |
Familial pulmonary fibrosis with surfactant genes mutations (SFTPA1; SFTPA2; SFTPC; NKX2.1; ABCA3) or telomere gene mutations (TERT; TERC; RTEL1; PARN; DKC1; TINF2; NOP10; NHP2; ACD; NAF1; ZCCHC8; RPA; POT1) | [11,12] |
Drug-induced ILDs | [9,13] |
Rheumatoid arthritis | [9,14] |
Systemic sclerosis | [9,15] |
ANCA-associated vasculitis | [16] |
Anti-synthethase syndrome | [9,17] |
Hermansky–Pudlak syndrome | [18] |
2. Materials and Methods
3. Case Presentation
3.1. Case #1
3.2. Case #2
3.3. Case #3
4. Discussion
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Richeldi, L.; Collard, H.R.; Jones, M.G. Idiopathic pulmonary fibrosis. Lancet 2017, 389, 1941–1952. [Google Scholar] [PubMed]
- Raghu, G.; Remy-Jardin, M.; Richeldi, L.; Thomson, C.C.; Inoue, Y.; Johkoh, T.; Kreuter, M.; Lynch, D.A.; Maher, T.M.; Martinez, F.J.; et al. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am. J. Respir. Crit. Care Med. 2022, 205, e18–e47. [Google Scholar] [CrossRef] [PubMed]
- Shu, C.C.; Chen, P.S.; Lin, Z.H.; Hsiao, C.T.; Kuo, C.C.; Chiang, H.Y.; Wu, P.C. Prevalence and risk factors of non-tuberculous mycobacterial pulmonary isolates and infection in interstitial lung disease associated with systemic autoimmune disease. Clin. Exp. Rheumatol. 2024, 42, 1006–1014. [Google Scholar] [CrossRef] [PubMed]
- Park, S.-W.; Song, J.W.; Shim, T.S.; Park, M.-S.; Lee, H.-L.; Uh, S.-T.; Park, C.-S.; Kim, D.S. Mycobacterial Pulmonary Infections in Patients with Idiopathic Pulmonary Fibrosis. J. Korean Med. Sci. 2012, 27, 896–900. [Google Scholar] [CrossRef]
- Akhter, N.; Rizvi, N.A. Interstitial Lung Diseases misdiagnosed as tuberculosis. Pak. J. Med. Sci. 2018, 34, 338–341. [Google Scholar] [CrossRef]
- Chung, M.J.; Goo, J.M.; Im, J.G. Pulmonary tuberculosis in patients with idiopathic pulmonary fibrosis. Eur. J. Radi-Ology 2004, 52, 175–179. [Google Scholar]
- Faverio, P.; De Giacomi, F.; Bodini, B.D.; Stainer, A.; Fumagalli, A.; Bini, F.; Luppi, F.; Aliberti, S. Nontuberculous mycobacterial pulmonary disease: An integrated approach beyond antibiotics. ERJ Open Res. 2021, 7, 00574–2020. [Google Scholar] [CrossRef]
- Lee, Y.-H.; Cha, S.-I.; Lim, J.-K.; Yoo, S.-S.; Lee, S.-Y.; Lee, J.; Kim, C.-H.; Park, J.-Y. Clinical and radiological features of pulmonary tuberculosis in patients with idiopathic pulmonary fibrosis. Respir. Investig. 2019, 57, 544–551. [Google Scholar] [CrossRef]
- Luppi, F.; Manfredi, A.; Faverio, P.; Andersen, M.B.; Bono, F.; Pagni, F.; Salvarani, C.; Bendstrup, E.; Sebastiani, M. The usual Interstitial pneumonia pattern in autoimmune rheumatic diseases. BMC Pulm. Med. 2023, 23, 501. [Google Scholar] [CrossRef]
- Shigemitsu, H.; Azuma, A. Sarcoidosis and interstitial pulmonary fibrosis; two distinct disorders or two ends of the same spectrum: Current Opinion in Pulmonary Medicine. Curr. Opin. Pulm. Med. 2011, 17, 303–307. [Google Scholar]
- Borie, R.; Kannengiesser, C.; Antoniou, K.; Bonella, F.; Crestani, B.; Fabre, A.; Froidure, A.; Galvin, L.; Griese, M.; Grutters, J.C.; et al. European Respiratory Society statement on familial pulmonary fibrosis. Eur. Respir. J. 2022, 61, 2201383. [Google Scholar] [CrossRef]
- Monteleone, G.; Bergantini, L.; D’Alessandro, M.; Pianigiani, T.; Simonetti, J.; Iovene, B.; Varone, F.; Sgalla, G.; Richeldi, L.; Bargagli, E.; et al. The Management of Familial Pulmonary Fibrosis in Different Medical Settings: Where Does that Leave Us? An Italian Nationwide Survey. Sarcoidosis Vasc. Diffus. Lung Dis. 2024, 41, e2024047. [Google Scholar] [CrossRef]
- Distefano, G.; Fanzone, L.; Palermo, M.; Tiralongo, F.; Cosentino, S.; Inì, C.; Galioto, F.; Vancheri, A.; Torrisi, S.E.; Mauro, L.A.; et al. HRCT Patterns of Drug-Induced Interstitial Lung Diseases: A Review. Diagnostics 2020, 10, 244. [Google Scholar] [CrossRef]
- Spagnolo, P.; Lee, J.S.; Sverzellati, N.; Rossi, G.; Cottin, V. The Lung in Rheumatoid Arthritis: Focus on Interstitial Lung Disease. Arthritis Rheumatol. 2018, 70, 1544–1554. [Google Scholar]
- Bernstein, E.J.; Boin, F.; Elicker, B.; Luo, Y.; Ren, Y.; Zhang, M.; Varga, J.; Assassi, S. FAM13A polymorphism is associated with a usual interstitial pneumonia pattern in patients with systemic sclerosis-associated interstitial lung disease. Rheumatology 2024, keae573. [Google Scholar] [CrossRef]
- Kadura, S.; Raghu, G. Antineutrophil cytoplasmic antibody-associated interstitial lung disease: A review. Eur. Respir. Rev. 2021, 30, 210123. [Google Scholar] [CrossRef]
- Ritesh, A.; Maturu, V.N.; Lakshman, A.; Bal, A.; Dhir, V.; Sharma, A.; Garg, M.; Saikia, B. Antisynthetase syndrome: An under-recognized cause of interstitial lung disease. Lung India 2016, 33, 20–26. [Google Scholar] [CrossRef]
- Donnan, M.; Ellis, S.; Glaspole, I. Hermansky-Pudlak Syndrome: An unusual pattern of pulmonary fibrosis. Respir. Med. Case Rep. 2024, 52, 102123. [Google Scholar] [CrossRef]
- Hayashi, M.; Takayanagi, N.; Kanauchi, T.; Miyahara, Y.; Yanagisawa, T.; Sugita, Y. Prognostic Factors of 634 HIV-Negative Patients with Mycobacterium avium Complex Lung Disease. Am. J. Respir. Crit. Care Med. 2012, 185, 575–583. [Google Scholar] [CrossRef]
- Nam, H.-S.; Jeon, K.; Um, S.-W.; Suh, G.Y.; Chung, M.P.; Kim, H.; Kwon, O.J.; Koh, W.-J. Clinical characteristics and treatment outcomes of chronic necrotizing pulmonary aspergillosis: A review of 43 cases. Int. J. Infect. Dis. 2010, 14, e479–e482. [Google Scholar] [CrossRef]
- Nakamoto, K.; Takayanagi, N.; Kanauchi, T.; Ishiguro, T.; Yanagisawa, T.; Sugita, Y. Prognostic Factors in 194 Patients with Chronic Necrotizing Pulmonary Aspergillosis. Intern. Med. 2013, 52, 727–734. [Google Scholar] [CrossRef] [PubMed]
- Hwang, H.J.; Kim, M.Y.; Shim, T.S.; Kim, D.S. Nontuberculous Mycobacterial Pulmonary Infection in Patients With Idiopathic Inter-stitial Pneumonias: Comparison with Patients Without Idiopathic Interstitial Pneumonias. J. Comput. Assist. Mography 2014, 38, 972–978. [Google Scholar] [CrossRef] [PubMed]
- Fibla, J.J.; Brunelli, A.; Allen, M.S.; Wigle, D.; Shen, R.; Nichols, F.; Deschamps, C.; Cassivi, S.D. Microbiology specimens obtained at the time of surgical lung biopsy for interstitial lung disease: Clinical yield and cost analysis. Eur. J. Cardio-Thorac. Surg. 2011, 41, 36–38. [Google Scholar] [CrossRef] [PubMed]
- Odashima, K.; Kagiyama, N.; Kanauchi, T.; Ishiguro, T.; Takayanagi, N. Incidence and etiology of chronic pulmonary infections in patients with idiopathic pulmonary fibrosis. PLoS ONE 2020, 15, e0230746. [Google Scholar] [CrossRef]
- Alpay Kanitez, N.; Celik, S.; Yilmaz Oner, S.; Urer, H.N.; Bes, C.; Cetinkaya, E. Cavitary pulmonary nodules in rheumatoid arthritis; case reports and review of the literature. Eur. J. Rheumatol. 2018, 5, 65–68. [Google Scholar] [CrossRef]
- Koslow, M.; Young, J.R.; Yi, J.; Baqir, M.; Johnson, G.B.; Ryu, J. Rheumatoid pulmonary nodules: Clinical and imaging features compared with malignancy. Eur. Radiol. 2019, 29, 1684–1692. [Google Scholar] [CrossRef]
- Brode, S.K.; Jamieson, F.B.; Ng, R.; Campitelli, M.A.; Kwong, J.C.; Paterson, J.M.; Li, P.; Marchand-Austin, A.; Bombardier, C.; Marras, T.K. Increased risk of mycobacterial infections associated with anti-rheumatic medications. Thorax 2015, 70, 677–682. [Google Scholar] [CrossRef]
- Uno, S.; Asakura, T.; Morimoto, K.; Yoshimura, K.; Uwamino, Y.; Nishimura, T.; Hoshino, Y.; Hasegawa, N. Comorbidities associated with nontuberculous mycobacterial disease in Japanese adults: A claims-data analysis. BMC Pulm. Med. 2020, 20, 262. [Google Scholar] [CrossRef]
- Yoo, J.-W.; Jo, K.-W.; Kang, B.-H.; Kim, M.Y.; Yoo, B.; Lee, C.-K.; Kim, Y.-G.; Yang, S.-K.; Byeon, J.-S.; Kim, K.-J.; et al. Mycobacterial diseases developed during anti-tumour necrosis factor-α therapy. Eur. Respir. J. 2014, 44, 1289–1295. [Google Scholar] [CrossRef]
- Oh, S.Y.; Kim, M.Y.; Hwang, H.J.; Shim, T.S.; Choi, C.M.; Kim, S.S.; Kim, D.S. Newly Detected Pulmonary Nontuberculous Mycobacterial Infection and Peripheral Lung Cancers in Patients During Follow-Up of Idiopathic Interstitial Pneumonia: Comparison of CT Findings. Medicine 2015, 94, e691. [Google Scholar] [CrossRef]
- Shachor, Y.; Schindler, D.; Siegal, A.; Lieberman, D.; Mikulski, Y.; Bruderman, I. Increased incidence of pulmonary tuberculosis in chronic interstitial lung disease. Thorax 1989, 44, 151–153. [Google Scholar] [CrossRef] [PubMed]
- Licata, M.A.; Mencarini, P.; Mastrobattista, A.; Carli, S.M.; Cerva, C.; Mosti, S.; Libertone, R.; Zolezzi, A.; Vittozzi, P.; Nisii, C.; et al. Clinical Utility of Induced Sputum and Bronchoalveolar Lavage Cultures in Diagnosing Nontuberculous Mycobacterial Pulmonary Disease. Pathogens 2024, 13, 1064. [Google Scholar] [CrossRef] [PubMed]
- Gupta, E.; Agarwal, P.; Gupta, A.; Prakash, P.; Dasgupta, A. Comparison of Induced Sputum and Bronchoalveolar Lavage Fluid Examination in the Diagnosis of Sputum Negative Pulmonary Tuberculosis. Indian J. Chest Dis. Allied Sci. 2022, 58, 173–175. [Google Scholar] [CrossRef]
- Ali, J. A multidisciplinary approach to the management of nontuberculous mycobacterial lung disease: A clinical perspective. Expert Rev. Respir. Med. 2021, 15, 663–673. [Google Scholar] [CrossRef]
- Lamb, Y.N. Nintedanib: A Review in Fibrotic Interstitial Lung Diseases. Drugs 2021, 81, 575–586. [Google Scholar]
- Lasky, J.A.; Criner, G.J.; Lazarus, H.M.; Kohlbrenner, V.; Bender, S.; Richeldi, L. Safety of Nintedanib in Patients with Idiopathic Pul-monary Fibrosis: Global Pharmacovigilance Data. Adv. Ther. 2020, 37, 4209–4219. [Google Scholar] [CrossRef]
- Bendstrup, E.; Wuyts, W.; Alfaro, T.; Chaudhuri, N.; Cornelissen, R.; Kreuter, M.; Nielsen, K.M.; Münster, A.-M.B.; Myllärniemi, M.; Ravaglia, C.; et al. Nintedanib in Idiopathic Pulmonary Fibrosis: Practical Management Recommendations for Potential Adverse Events. Respiration 2019, 97, 173–184. [Google Scholar] [CrossRef]
- Watanabe, M.; Hagiwara, E.; Shintani, R.; Hiramatsu, Y.; Ikeda, S.; Okuda, R.; Sekine, A.; Baba, T.; Komatsu, S.; Ogura, T. Clinical characteristics of pulmonary Mycobacterium avium complex disease in patients with interstitial lung disease. J. Infect. Chemother. 2024, 31, 102515. [Google Scholar] [CrossRef]
Sex/ Age * | Smoking Status | Timing of Diagnoses ** | Clinical Presentation | ILD Pattern/ Diagnosis | NTM/TB Radiological Pattern | Biological Sample | Microbiology | ILD and NTM/TB Treatment | Patient Outcome | |
---|---|---|---|---|---|---|---|---|---|---|
#1 | M/76 | Former | Three-year history of CTD-ILD before NTM infection | Massive hemoptysis, type 1 respiratory failure requiring hospital admission | Definite UIP CTD (RA)-ILD | Fibrocavitary | BAL | M. kansasii | Azathioprine rifampicin, azithromycin, and ethambutol | Alive |
#2 | F/82 | Former | CTD-ILD prior to TB | Worsening of cough, dyspnea, and weight loss; type 1 respiratory failure requiring hospital admission | Definite UIP-CTD (RA)-ILD | Fibrocavitary | BAL | MDR Mtb | Amikacin, amoxicillin/clavulanate, meropenem, clofazimin, cicloserin, bedaquilin, and moxifloxacin | Died before completing therapy |
#3 | M/70 | Former | concomitant diagnoses | productive cough and dyspnea on exertion | Definite UIP-IPF | Bronchiectatic | Induced sputum | Mtb | Nintedanib, rifampicin, isoniazid, ethambutol, pyrazinamide, (moxifloxacine) | Alive |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Licata, M.A.; Monteleone, G.; Schiavi, E.; Musso, M.; Mencarini, P.; Mastrobattista, A.; Carli, S.M.; Cerva, C.; Sgalla, G.; Richeldi, L.; et al. Usual Interstitial Pneumonia Pattern and Mycobacteria Lung Diseases: A Case Series. Infect. Dis. Rep. 2025, 17, 28. https://doi.org/10.3390/idr17020028
Licata MA, Monteleone G, Schiavi E, Musso M, Mencarini P, Mastrobattista A, Carli SM, Cerva C, Sgalla G, Richeldi L, et al. Usual Interstitial Pneumonia Pattern and Mycobacteria Lung Diseases: A Case Series. Infectious Disease Reports. 2025; 17(2):28. https://doi.org/10.3390/idr17020028
Chicago/Turabian StyleLicata, Maria Angela, Giorgio Monteleone, Enrico Schiavi, Maria Musso, Paola Mencarini, Annelisa Mastrobattista, Serena Maria Carli, Carlotta Cerva, Giacomo Sgalla, Luca Richeldi, and et al. 2025. "Usual Interstitial Pneumonia Pattern and Mycobacteria Lung Diseases: A Case Series" Infectious Disease Reports 17, no. 2: 28. https://doi.org/10.3390/idr17020028
APA StyleLicata, M. A., Monteleone, G., Schiavi, E., Musso, M., Mencarini, P., Mastrobattista, A., Carli, S. M., Cerva, C., Sgalla, G., Richeldi, L., Palmieri, F., & Gualano, G. (2025). Usual Interstitial Pneumonia Pattern and Mycobacteria Lung Diseases: A Case Series. Infectious Disease Reports, 17(2), 28. https://doi.org/10.3390/idr17020028